一个β-内啡冠的形成减轻了阿尔茨海默氏症的氨基代
Yunxiang Sun1,2, Nicholas Andrikopoulos3, Guofang Zhang4
1School of Physical Science and Technology, Ningbo University, Ningbo, 315211, China.
Small (Weinheim an der Bergstrasse, Germany)
|May 19, 2025
概括
定期炼会释放β-endorphin,这种β-endorphin在粉样β聚合物周围形成一个保护性的"冠状". 这种相互作用减轻了阿尔茨海默病的病理和毒性,揭示了运动效益背后的一个关键机制.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 生物物理学的生物物理.
背景情况:
- 阿尔茨海默病 (AD) 的特征是大脑中的粉样β (Aβ) 斑块.
- 定期体育炼与阿尔茨海默病风险降低有关.
研究的目的:
- 研究运动期间释放的β-内啡与Aβ聚合毒性相互作用并减轻的分子机制.
- 探索这种相互作用作为AD治疗策略的潜力.
主要方法:
- 在体外生物物理表征.
- 在 silico 原子的离散分子动力学模拟.
- 在体内细胞活力,免疫光和西部涂抹试验.
主要成果:
- 贝塔-内啡与Aβ直接相互作用,在聚合物周围形成一个保护性的"冠状体".
- 这种冠状体保护细胞免受Aβ毒性的影响.
- 这种相互作用在体内显著抑制了Aβ毒性.
结论:
- 贝塔内多芬通过直接的分子相互作用减轻了Aβ聚合毒性.
- 这为体育炼的神经保护作用提供了一个新的分子机制.
- 这些发现可以指导开发新的AD疗法和预防策略.
相关概念视频
Amyloid Fibrils
9.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.1K
Alzheimer's Disease: Overview
396
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
396
Alzheimer's Disease: Treatment
136
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
136


